The protein wars

BellRing Brands makes Premier Protein, the number one ready-to-drink protein shake in the country. At its peak in late 2024 the stock traded near $80. A year ago it was around $40. Today it's sitting at about $10, which is roughly 7 times earnings, and the whole company, debt included, goes for about 8 times this year's cash profit. When a market leader loses 75% of its value in a year while its product is still selling more units than last year, one of two things is true: either the business broke, or the market is mispricing a bad year. I'm going to walk you through the whole situation, show you the math on both answers, and tell you exactly what I'm watching to decide between them.

The background in two minutes

BellRing sells protein in two forms. Premier Protein shakes are about 82% of revenue, roughly $2 billion a year. Dymatize protein powder is another 12%. The company owns no factories and no trucks. Contract manufacturers make everything, and the product ships through the retailers' own warehouses, so BellRing spends about $10 million a year on equipment against $2.35 billion of revenue. About 74% of sales run through three customers: Walmart with Sam's Club, Costco, and Amazon.

For years this was a great setup. The protein category was growing anywhere between 11% and 16% a year, powered by GLP-1 users protecting muscle and a culture where every label in the store now advertises grams of protein. BellRing was earning EBITDA margins around 21%. EBITDA margin, meaning the cash profit of the business before interest, taxes, and accounting depreciation, is the cleanest way to compare a business like this year to year.

Then fiscal 2026 happened, and three problems hit at once:

1. Input costs exploded. Whey protein concentrate, the main ingredient, went up 108% in two years. The premium isolate went up about 139%. The same protein boom that was filling BellRing's sales line was draining the dairy supply it buys from.
2. Coca-Cola showed up. Coke's fairlife brand, and specifically its Core Power shakes, grew from about $10 million in retail sales in 2014 to over $4 billion now, and it reached rough share parity with Premier. On top of that, roughly forty smaller protein brands entered the category in eighteen months, and BellRing spent heavily on promotions to defend its shelf space.
3. They beat themselves up too. A $10 million writedown on excess shake bottles they over-ordered, another $11 million on a defective ingredient from a supplier, about $7 million in extra spend to clear the surplus, several guidance cuts, and in July the CEO who built the company retired.

The result: margins fell from about 21% to about 12%, and the stock followed. The low was $7.82, printed on the exact day of the ugly August earnings report, and the stock has held above that level since.

The thesis

Here is the case, in the order the logic runs. Each step has a number attached, because a thesis you can't test with numbers is just a story.

Step 1: Demand is fine. This is a cost and competition problem, not a customer problem. Consumption of Premier shakes grew 6% last quarter. Household penetration is about 23%, the highest in the category, and so is the repeat purchase rate. And the revenue is honest, meaning they're not channel stuffing, which is when a company ships extra product into its retailers to dress up the sales line. You check that by comparing what the company shipped against what actually sold at the register: last quarter shipments grew 4.2% while sell-through grew 6%, so the retailers were drawing their inventories down, which is the opposite of stuffing. Compare all of that to Kraft Heinz in 2019, the famous value trap, where the customers were actually leaving the brands. When volume is falling, no turnaround fixes it. When volume is growing, the sales are clean, and margins collapsed, you're looking at a cycle, and cycles end.

Step 2: The margin problem has a specific, dated fix. BellRing is raising Premier prices by double digits in October, with more pricing on powders. And there is already proof inside the company's own numbers that its customers tolerate a price increase: Dymatize took over 20% pricing last quarter and its volume still grew 6%. On the cost side, the whey shortage is getting a supply response, with new processing capacity coming online in late 2026 and 2027. Pricing arrives first, cost relief arrives second.

Step 3: The business is very hard to kill in the meantime. Because everything is outsourced, the costs are variable. I modeled the floor: the EBITDA needed to cover interest, taxes, and equipment spending is about $90 million, under 4% of revenue, versus roughly $285 million guided for this year. Even if Premier's share drifted from 25% down toward 18% over several years with margins stuck at the bottom, the company still generates about $150 million a year of free cash and pays down debt while it waits.

Step 4: The market is pricing zero recovery. At $10, with about $1.05 billion of net debt against $285 million of EBITDA, the whole enterprise is valued at roughly 8 times a trough year. For that price you're being told margins never recover and the business never grows again, for a brand whose product is still growing volume 6% a year. That's the bet on the other side of the trade.

Step 5: The catalysts have dates. Mid-November brings the fiscal 2026 results and the new CEO's first full-year guidance. Early February brings the first quarter that actually contains the October price increase. By February, this question is largely answered, one way or the other.

Where the margins actually come from

The recovery math has to be specific, so here is the bridge from 12% back toward 16%:

• One-time charges roll off: +1.2 points. The $28 million of inventory writedowns was this year's mess, not a recurring cost.
• October pricing: +2 to +3 points. Double-digit pricing on 82% of revenue, netted against the volume you lose and the promotions you keep running.
• Whey relief: +1 to +2 points. New supply capacity lands in late 2026 and 2027, and it flows through the profit line about two quarters after spot prices turn.
• Restructuring: +0.5 points. Management announced $10 to $12 million of annual overhead savings.
• Competitive give-back: minus 1 to 2 points. Coca-Cola doesn't stop pressing, so some of the pricing gets recycled into defending shelf space.

Net result: 15% to 17% margins by fiscal 2028 is the credible middle path. Getting back to the old 21% would need both a promo truce with fairlife and a full whey reversion, and I wouldn't underwrite either.

One thing I want to call out: there is not much room to cut overhead beyond what's announced. Total selling and admin costs run about $330 million a year, around 14% of revenue, and the biggest discretionary piece of that is advertising and marketing, which is the one thing you cannot cut while Coca-Cola is attacking. Cutting brand spend to make the margin is exactly how Kraft Heinz destroyed itself. The recovery is a gross margin story, meaning pricing versus ingredient costs. It is not a cost-cutting story, and if management starts selling it as one, that's a bad sign, not a good one.

A quick word on the famous returns on capital, because the 50% ROIC number shows up in every bull writeup of this stock. It's arithmetically real and analytically misleading. The returns are high because the capital sits on the contract manufacturers' balance sheets, not BellRing's, and BellRing rents it through fees buried in the cost of goods. High ROIC here is a property of the business model, not proof of a moat, and it stays high in almost every scenario. So it tells you nothing about which scenario you're in. The signals that actually decide this are gross margin and the volume line.

The one number I anchor on

Here's the shorthand I use to sanity-check any consumer business, and it's the fastest way to see what the market is really saying about BellRing. A normal business should trade at a price-to-sales ratio that matches its normalized operating margin: if a business earns 17 cents of operating profit on every dollar of sales, it should trade at about 1.7 times sales. The logic underneath is that this works out to roughly 10 times operating income, which is about what a steady business is worth. And when a company carries real debt, you run the same math on enterprise value to sales instead of price to sales, because the debt holders own their slice of those sales before you do.

Run BellRing through it. The enterprise, meaning the $1.2 billion of stock plus the $1.05 billion of net debt, is valued at about $2.25 billion against $2.35 billion of sales. That's roughly 0.95 times sales, which under the shorthand means the market is pricing this as a business that earns about a 9% to 10% operating margin, permanently. The trough year they are in right now runs about 12% underneath the one-time charges. So the market is not just pricing zero recovery. It's pricing the business as slightly worse than the worst year it just had.

Now flip it forward. If the margin bridge above gets you to a normalized operating margin of 15% to 16%, the shorthand says fair value is about 1.5 to 1.6 times sales. On roughly $2.4 billion of revenue, that's an enterprise value of $3.6 to $3.8 billion, minus about $1 billion of debt, divided by 116 million shares, which lands anywhere between $22 and $24 a share. That's a completely different method from the scenario table below, and it gets you very close to the same number as the base case. When two completely different methods land in the same place, that tells you the answer is probably in the right range.

Two warnings that come with the shorthand. First, be careful with plain price-to-sales on a levered company: BellRing's stock trades at only about 0.5 times sales, which looks even cheaper, and that extra cheapness is fake, because the debt sits in front of you. That's exactly why the rule runs on enterprise value. Second, the same one number was screaming the opposite message at the top. At $80, the enterprise was valued at about 5 times sales, which under the shorthand means the market was pricing a 50% operating margin, and no packaged goods company on earth earns a 50% operating margin. The only way that price ever made sense was double-digit growth continuing for years with no competition showing up, and what actually showed up was forty competitors and Coca-Cola.

One boundary on the rule before you go using it everywhere: it's built for brand-based, asset-light businesses like this one, where sales and margin are the whole story. For heavy-asset businesses, meaning manufacturers, utilities, anything where the plant is the business, book value and return on invested capital drive the number, and the sales shorthand will point you the wrong way.

The projections: upside, downside, and what it nets to

Here is how I stress-test it. About 116 million shares, $1.05 billion of net debt, stock at $10.40. Four scenarios for fiscal 2028, each with the probability I'd assign today:

The per-share values apply a 6.5 to 9.5 times multiple on that year's EBITDA, subtract the debt that would remain after the interim cash flow, and divide by the shares. They are scenario math, not price targets.

Weight it out and the expected value is about $17 against a $10.40 stock, roughly 60% higher, over about two years. The shape matters more than the average: the probability-weighted gain runs about eight times the probability-weighted loss. That's what an asymmetric setup looks like on paper. The reason the downside stays contained in three of the four scenarios is Step 3: a variable-cost business with a growing product doesn't burn cash while you wait to find out.

The tail scenario is the one that deserves respect. Three customers are 74% of sales with no long-term contracts, and the debt is what turns that from a bad year into a near-wipeout: $840 million of notes at a 7% coupon, taken on partly to buy back $477 million of stock at an average of $53. The leverage amplifies everything, in both directions.

Where the return actually comes from

A projection is not finished until you say where the money shows up, so here is the base case over the next two years, broken down source by source.

• Dividends: zero. BellRing doesn't pay one and shouldn't, because every spare dollar has a better job while the notes cost 7%.
• Share repurchases: small, and I want them small. There's $507 million of buyback authorization sitting there, and at this debt level it's a temptation, not an asset. I'd expect anywhere between $100 and $150 million of repurchases late in the window, which retires about 5% of the shares. Remember: the last round bought $477 million of stock at an average of $53 with borrowed money. That lesson was expensive, and I want to see that it was learned.
• Reinvestment in the business: close to zero, by design. Growth here needs no capital, which is the beauty of the model and also the reason forty competitors could rent the same model.
• Debt paydown: the second-biggest piece. Roughly $270 to $300 million of free cash goes against the debt over two years. At a flat enterprise value, every dollar of debt paid down transfers a dollar from the creditors to the equity, and on a $1.2 billion market cap that transfer alone is worth about 25% before anything else goes right.
• Earnings recovery: the biggest piece. EBITDA going from $285 million toward $375 million at an unchanged multiple adds roughly $700 million of enterprise value, which is about 60% of the base-case gain.
• Revaluation: the piece I count on least, on purpose. The base case only moves the multiple from about 8 to 8.5 times, which is under 20% of the gain. If the multiple never moves at all, the base case still returns about 75% over the two years from recovery plus paydown plus buybacks.

Add it up and the base case runs roughly 40% a year for two years, built out of earnings recovery and debt paydown rather than out of the market changing its mind. That's the structure I want in anything I own: revaluation as the kicker, never the thesis.

The risks, named and sized

1. Coca-Cola doesn't cooperate. fairlife's growth was capacity-constrained for years, and that constraint is expiring: a $650 million plant in New York started ramping in August, and another $650 million expansion in Michigan was announced in March. New Core Power supply arrives in the same quarters BellRing raises prices. If fairlife holds its price and promotes into the increase, the Stall scenario becomes the base case. Coke's October earnings call is the first read.
2. Whey stays expensive. The new supply capacity is scheduled, not delivered. If dairy protein stays tight through 2027, the margin bridge loses its second-biggest plank and recovery pushes out a full year.
3. The club channel. A lost Costco rotation can take something like 15% of revenue in a quarter. Nothing in the current data suggests it, and Premier's velocity is the best argument it doesn't happen, but with 74% concentration it's the risk that never fully goes away.
4. The November guide will look bad on purpose. A new CEO's first guidance is an anchor, not a forecast. He just walked in, nothing is his fault yet, and every incentive says set the bar low, blame the old regime, and beat the number for two years. Understand that going in: a grim November guide with a healthy volume assumption inside it is normal, and the selloff it can trigger is often the best entry these setups produce. What would actually break the thesis is not a low guide, it's pricing failing or volumes cracking.

On management: the new CEO, Michael Axelrod, spent most of his career on the manufacturing side of the industry, running contract manufacturers and private-label operations, which is the right background for an operations cleanup. Sixty percent of his equity pays on three-year stock performance against a peer group, and his first grant was struck in late July at about $13, days before the stock broke to $7.82, so at today's price he starts underwater on his own package. That sharpens the incentive rather than dulling it, and his payoff is levered to the same variable as the whole thesis. I'd also note, cynically, that new CEOs are half-expected to buy stock as a gesture, so if a purchase comes, judge it against his roughly $2 million cash pay. A couple hundred thousand dollars is a press release. A seven-figure check of his own money is information. And be careful reading the filings on this one: most of what shows up as insiders "acquiring" shares here is grants and deferred director fees, not buying. The actual open-market record since the collapse is one director's $37,000 purchase, while the chairman sold about $3.8 million within months of the top.

What I'm watching between now and February

Five things, weekly, all public and free:

1. USDA whey prices, published every Thursday. A sustained rollover shows up in gross margin two quarters later.
2. The shelf price of a Premier twelve-pack at the clubs starting in October, against its Amazon rank. That pair says whether pricing sticks while volume holds.
3. fairlife's pricing behavior on the same shelves, plus Coca-Cola's October call.
4. Wall Street's estimate revisions. In every comparable case, the stock bottomed when estimates stopped falling, about one to two quarters before the recovery showed up in reported numbers.
5. Insider buying, judged by size against salary, not by the headline.

The decision rule I wrote down in advance: this becomes a buy for me when pricing is holding with volume down less than management's own elasticity guide, Coca-Cola is following rather than attacking, revisions have gone flat, and the club channel shows no cracks. If those line up into a November selloff, that's the asymmetry. If pricing fails or a club wobbles, I walk away, because the tail scenario with this much debt is not something you average into.

I don't own BellRing shares as I write this, and whether I ever do depends on that checklist, not on how well this essay argues.

Nothing here is investment advice. It's a record of how I think about one situation, written before the outcome is known, which is the only honest time to write it.

Sources

Every number in this piece comes from public filings and public data. The load-bearing ones, so you can check my work:

• BellRing Brands fiscal Q3 2026 results, August 4, 2026: quarterly results, the guidance, the inventory charges, Dymatize pricing and volume, shipments versus consumption.
• BellRing Brands fiscal 2025 Form 10-K: customer concentration, contract manufacturer concentration, segment mix, the buyback history.
• BellRing fiscal Q3 2026 earnings call: household penetration, category share structure, the October pricing plan.
• Form 8-K of July 8, 2026: the CEO transition and Michael Axelrod's compensation package.
• SEC Form 4 filings for BellRing: the insider buying and selling record.
• USDA Dairy Market News, weekly whey report: whey protein concentrate and isolate prices, published every Thursday, free.
• Food Dive on the protein category: the roughly forty new entrants and the first decline in ready-to-drink household spending in five years.
• Coca-Cola on the Webster, New York fairlife plant and the Rochester Business Journal on its production ramp, plus fairlife on the $650 million Michigan expansion.
• Liquid Opportunities on fairlife's growth: the $10 million to $4 billion arc.

The scenario numbers, probabilities, and the margin bridge are my own math built on those inputs, and they are the part most worth arguing with.